Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors

Taniguchi, Kyoko; Yoshihara, Satoshi; Maruya, Etsuko; Ikegame, Kazuhiro; Kaida, Katsuji; Hayashi, Kouji; Kato, Ruri; Inoue, Takayuki; Fujioka, Tatsuya; Tamaki, Hiroya; Okada, Masaya; Onuma, T; Fujii, Nobuharu; Kusunoki, Yasushi; Soma, Toshihiro; Saji, Hiroh; Ogawa, Hiroyasu

doi:10.1038/bmt.2012.28

Cited by 18 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the auto-Ab against RP155, donor-derived LLPCs may contribute to the auto-Ab production. This hypothesis was partially supported by the fact that donor-derived HLA Abs were produced after HSCT from HLA-Ab-positive donors, but the Ab titer kinetics between our study and Taniguchi et al 11 was quite different; the anti-HLA Ab peaked shortly after HSCT and then gradually decreased, whereas the nucleolar pattern of ANAs in our patient emerged months after HSCT and thereafter gradually increased, which implies that different mechanisms underlie the two cases. Donor CD4 + T cells may contribute to the expansion of plasmablasts and LLPCs, as is the case with the WT1-peptide immunization model.…”

supporting

confidence: 47%

Changes in the autoantibody pattern during allogeneic stem-cell transplantation for acute myeloid leukemia complicated by systemic lupus erythematosus

Arita

Murakami

Wada

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

supporting

confidence: 47%

Changes in the autoantibody pattern during allogeneic stem-cell transplantation for acute myeloid leukemia complicated by systemic lupus erythematosus

Arita

Murakami

Wada

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Emergence of antibodies to HLA antigens is often associated with disorders such as graft failure and resistance to transfusion [23][24][25][26][27]. This study is the first to find that anti-HLA antibodies also can be used therapeutically.…”

Section: Discussionmentioning

confidence: 94%

Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model

Nakauchi

Yamazaki

Napier

et al. 2015

Experimental Hematology

View full text Add to dashboard Cite

Graft-versus-host disease (GVHD), mediated by donor-derived alloreactive T cells, is a major cause of nonrelapse mortality in allogeneic hematopoietic stem cell transplantation. Its therapy is not well-defined. We established allele-specific anti-human leukocyte antigen (HLA) monoclonal antibodies (ASHmAbs) that specifically target HLA molecules, with steady death of target-expressing cells. One such ASHmAb, against HLA-A*02:01 (A2-kASHmAb), was examined in a xenogeneic GVHD mouse model. To induce fatal GVHD, non-irradiated NOD/Shi-scid/IL-2Rγ(null) mice were injected with healthy donor human peripheral blood mononuclear cells, some expressing HLA-A*02:01, some not. Administration of A2-kASHmAb promoted the survival of mice injected with HLA-A*02:01-expressing peripheral blood mononuclear cells (p < 0.0001) and, in humanized NOD/Shi-scid/IL-2Rγ(null) mice, immediately cleared HLA-A*02:01-expressing human blood cells from mouse peripheral blood. Human peripheral blood mononuclear cells were again detectable in mouse blood 2 to 4 weeks after A2-kASHmAb administration, suggesting that kASHmAb may be safely administered to GVHD patients without permanently ablating the graft. This approach, different from those in existing GVHD pharmacotherapy, may open a new door for treatment of GVHD in HLA-mismatched allogeneic hematopoietic stem cell transplantation.

show abstract

“…The use of HLA-mismatched cord blood and related haploidentical donors has led to more transplants being performed where the patient has antibodies directed against HLA specificities present in the donor (donor-specific antibodies, DSA). Recent studies indicate that DSA in the recipient is a significant risk factor for transplant nonengraftment (Ciurea et al, 2011;Taniguchi et al, 2012).…”

Section: Hla Alloantibodiesmentioning

confidence: 99%

BSHI Guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation

Little

Green

Harvey

et al. 2016

Int J Immunogenetics

View full text Add to dashboard Cite

List of recommendations• All laboratories performing H&I testing for allogeneic HPC transplantation should follow EFI standards and be accreditated by EFI and UKAS/CPA. (Grade 1A)• HLA typing definitions as described by Nunes et al. 2011 and here should be used (Grade 1A)• HLA typing results should use official WHO HLA Nomenclature (Grade 1A)• The clinical urgency should be made available to the individual performing the related and unrelated donor search (Grade 1B)• HLA high resolution typing should be performed on potential matching; mismatching and haploidentical related donors when familial haplotypes cannot be fully assigned (Grade 1A)• Patients and selected related donors should be typed for HLA-A, -B, -C, -DRB1 and -DQB1 (+/-DPB1) (Grade 1A).• All patients and donors must have their HLA type confirmed on a second sample pre-transplant (Grade 1A).• The patient should be high resolution typed prior to submitting the HLA type for an unrelated donor search (Grade 1A)• A 10/10 high resolution HLA-A, -B, -C, -DRB1 and -DQB1 matched unrelated PBSC or bone marrow donor should be used where possible (Grade 1A).• Where a 10/10 matched PBSC or bone marrow donor is not available a single mismatch at HLA-A, -B, -C, -DRB1 or -DQB1 is acceptable (Grade 1A).• Alternative progenitor cell donors (cord blood or haplo-identical) should be considered early in the donor search when a patient is unlikely to have an HLA matched unrelated donor (Grade 1A).• HLA-DRB3, -DRB4, -DRB5 typing should be performed and, when a choice of otherwise equally matched and appropriate (e.g. CMV status) donors is available, mismatches for these should be minimized (Grade 2A). • For unrelated donor selection, HLA-DPB1 typing should be performed and when a choice of otherwise equally matched and appropriate (e.g. CMV status) donors is available, non-permissive mismatches should be minimised (Grade 2C).• For mismatched related and unrelated donor selection, HVG mismatches are favoured over bi-directional and GVH mismatches (Grade 2C).• UCB units should be HLA typed to high resolution HLA-A, -B, -C, -DRB1, -DQB1 (Grade 1B ).• Selection of UCB units should follow national consensus guidelines published by Hough et al. (Grade 1A).• HLA alloantibody testing of the recipient should be performed at the time of donor search and should be repeated at the time of donor work-up request if an HLA mismatched donor is selected (Grade 1A).• The clinical team must be made aware of any HLA alloantibody incompatibility for a selected donor (Grade 1A).• When a choice of equally well matched donors is available, avoid selection of donors against which the patient has HLA alloantibodies (Grade 1A).• HLA alloantibody testing should be performed in cases of failed engraftment if the donor is HLA mismatched (Grade 1B).• The guideline published by Emery et al., 2013 recommending CMV matching between patient and donor should be followed (Grade 1A).• Major ABO incompatibilities should be avoided when there is a choice of HLA and CMV matched donors (Grade 1A)• Male donors ...

show abstract

Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors

Cited by 18 publications

References 30 publications

Changes in the autoantibody pattern during allogeneic stem-cell transplantation for acute myeloid leukemia complicated by systemic lupus erythematosus

Changes in the autoantibody pattern during allogeneic stem-cell transplantation for acute myeloid leukemia complicated by systemic lupus erythematosus

Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model

BSHI Guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation

Contact Info

Product

Resources

About